West Pharmaceutical Services (WST)
(Delayed Data from NYSE)
$302.78 USD
+2.26 (0.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $302.74 -0.04 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$302.78 USD
+2.26 (0.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $302.74 -0.04 (-0.01%) 7:58 PM ET
5-Strong Sell of 5 5
F Value C Growth D Momentum F VGM
Zacks News
West Pharmaceutical Services (WST) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 23.61% and 1.68%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Jul 25: SYK, BAX & More
by Urmimala Biswas
Encouraging growth in the emerging markets is likely to be a bonus for the medical products space this earnings season.
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC vs. WST: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
HSIC vs. WST: Which Stock Is the Better Value Option?
West Pharmaceutical (WST) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
West Pharmaceutical (WST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ABC vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
ABC vs. WST: Which Stock Is the Better Value Option?
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
West Pharmaceutical Services (WST) Beats Q4 Earnings Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 1.39% and -2.87%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HSIC vs. WST: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. WST: Which Stock Is the Better Value Option?
West Pharmaceutical Services (WST) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 7.04% and 0.97%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
West Pharmaceutical Services (WST) Q3 Earnings Preview: What's in the Cards?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MedTech Stocks' Q4 Earnings on Feb 16: LH, WST and MDRX
by Zacks Equity Research
Let's take a look at the major MedTech stocks slated to release their fourth-quarter 2016 numbers on Feb 16.